echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The company completed a $13.4 million B1 round of financing to study in-cell drug use of PARP inhibitors

    The company completed a $13.4 million B1 round of financing to study in-cell drug use of PARP inhibitors

    • Last Update: 2021-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    June 20, 2019, Cybrexa Therapeutics, a company focused on research and development of cancer-targeted therapies, announced the completion of a $13.4 million B1 round of financing. The financing will be used to advance Cybrexa's first clinical development of the drug CBX-11 (alphalex™-rucaparib), as well as to accelerate the development of other projects in its preclinical pipeline. CBX-11 is being developed as an intravenous preparation using the FDA and EMA-approved PARP inhibitor rucaparib. It is given in union with tymoamine (TMZ) and/or other DNA damage agents.Cybrexa is committed to building a strong combination of oncology therapies that utilize alphaex ™ for antigen non-dependent in-cell drug delivery. Cybrexa's alphaalex™ is a tumor-targeted technology platform that enables small molecules to pass through cell membranes at low pH conditions, using acidic tumor micro-environments to selectively release drug molecules directly within tumor cells while limiting toxicity to healthy tissues. As a result, alphalex ™ technology -- made up of a new peptide, connecter, and small molecule anticancer -- allows antigen-independent, in-cell small molecule anticancer agents to enter tumor cells directly.so far, the company's total financing has reached $21.1 million. Cybrexa's existing investors - CT Innovations, HighCape Capital Special Opportunities Fund, Cycle Venture Partners - are all involved in this round of investments."We look forward to the first quarter of 2020, when the leading drug CBX-11 will be available for clinical use, and we hope to further develop more new therapeutic candidates using alphaex™ technology, which we believe has the transformative potential to improve tumor response and overall survival while limiting toxicity," said Per Hellsund, President and CEO of Cybrexa. (Creating a foreign exchange)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.